Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02337530 | Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC | completed | Phase 2 | 62 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02414139 | Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) | completed | Phase 2 | 373 | Novartis PharmaceuticalsINDUSTRY | 20 | Mar 20, 2024 |
| clinicaltrials |
| NCT04212052 | Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04310943 | Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma | completed | Phase 2 | 24 | Zhou ChengzhiOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT00020202 | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03976518 | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)(CHANCE) | completed | Phase 2 | 43 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04238169 | Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC | completed | Phase 2 | 60 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05005273 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 28, 2024 | clinicaltrials |
| NCT03360630 | Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC | completed | Phase 1 / Phase 2 | 60 | Capital Medical UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04577638 | Accelerated Radio-Immunotherapy for Lung Cancer(AIRING) | completed | Phase 2 | 8 | Center Eugene MarquisOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT01542437 | Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 66 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02073968 | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer(PAINT) | completed | Phase 2 | 35 | Albert Einstein College of MedicineOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02567799 | BIO 300 Non-Small Cell Lung Cancer Study(NSCLC) | completed | Phase 1 / Phase 2 | 21 | Humanetics CorporationINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT03087760 | Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | completed | Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03083691 | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | completed | Phase 2 | 90 | Lung Cancer Group CologneOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04620330 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer(RAMP202) | completed | Phase 2 | 90 | Verastem, Inc.INDUSTRY | 5 | Jan 12, 2024 | clinicaltrials |
| NCT02709720 | Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC(NORA) | completed | Phase 2 | 68 | Spanish Lung Cancer GroupOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02581943 | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | completed | Phase 2 | 43 | Wake Forest University Health SciencesOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04361825 | Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects(SUKSES-N4) | completed | Phase 2 | 42 | Se-Hoon LeeOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04939662 | Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects(SUKSES-B2) | completed | Phase 2 | 25 | Se-Hoon LeeOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04271384 | Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer | completed | Phase 2 | 25 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 24 | Shadia Jalal, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03845270 | Her2-positive Lung Cancer Treated With Dedicated Drug(R2D2) | completed | Phase 2 | 46 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04311034 | A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 37 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03014648 | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 28 | Liza Villaruz, MDOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02716038 | Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | completed | Phase 2 | 39 | Columbia UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02580994 | Pembrolizumab in Untreated Extensive SCLC(REACTION) | completed | Phase 2 | 125 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02183883 | Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity(DARWIN1) | completed | Phase 2 | 12 | University College, LondonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03409458 | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab(PAVE-1) | completed | Phase 1 / Phase 2 | 68 | Promontory Therapeutics Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT02407171 | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | completed | Phase 1 / Phase 2 | 61 | Yale UniversityOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02321540 | A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT01750281 | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.(SELECT-2) | completed | Phase 2 | 212 | AstraZenecaINDUSTRY | 8 | Oct 24, 2023 | clinicaltrials |
| NCT03727724 | Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer(AFACET) | completed | Phase 2 | 37 | The Netherlands Cancer InstituteOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03434418 | A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations | completed | Phase 2 | 17 | Duke UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03468985 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00590902 | Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT02426658 | Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02904954 | Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | completed | Phase 2 | 60 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT00602797 | Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02803203 | Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02439450 | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | Heat BiologicsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04790409 | Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations | completed | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT02343952 | Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | completed | Phase 2 | 93 | Nasser Hanna, M.D.OTHER | 1 | Sep 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 21, 2024source: clinicaltrials